Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284557 | 0.88 | KDM4E (0.39) | GRM5IRAK4FLT3MAPTDRD2 | |
| SCHEMBL4281443 | 0.88 | IRAK4 (0.38) | GRM5IRAK4FLT3DRD2DRD4 | |
| SCHEMBL4285756 | 0.85 | IRAK4 (0.40) | GRM5IRAK4FLT3DRD2DRD4 | |
| SCHEMBL4284524 | 0.85 | ALDH1A1 (0.43) | IRAK4FLT3MAPTL3MBTL1 | |
| SCHEMBL4287269 | 0.84 | MEN1 (0.41) | GRM5IRAK4FLT3DRD2DRD4 | |
| SCHEMBL4288206 | 0.84 | IRAK4 (0.37) | GRM5IRAK4FLT3DRD2DRD4 | |
| SCHEMBL4283524 | 0.84 | IRAK4 (0.40) | IRAK4FLT3DRD2DRD4 | |
| SCHEMBL4289532 | 0.84 | IRAK4 (0.41) | GRM5IRAK4FLT3DRD2DRD4 | |
| SCHEMBL4287669 | 0.81 | IRAK4 (0.44) | GRM5IRAK4FLT3 | |
| SCHEMBL4285098 | 0.81 | GRM5 (0.40) | GRM5IRAK4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | GRM5 3842/4885GPR6 3854/4885SMN1; SMN2 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.